Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Therapeutics: Q1 Earnings Snapshot

ESPR : 2.37 (+11.79%)
Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Therapeutics: Q4 Earnings Snapshot

ESPR : 2.37 (+11.79%)
Esperion Therapeutics: Q3 Earnings Snapshot

Esperion Therapeutics: Q3 Earnings Snapshot

ESPR : 2.37 (+11.79%)
Esperion Therapeutics: Q2 Earnings Snapshot

Esperion Therapeutics: Q2 Earnings Snapshot

ESPR : 2.37 (+11.79%)
Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

ADMA : 6.91 (unch)
ESPR : 2.37 (+11.79%)
ANIX : 2.91 (-3.64%)
ALLO : 2.91 (-3.32%)
Esperion Therapeutics (ESPR) Reports Q1 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -21.54% and 15.71%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ESPR : 2.37 (+11.79%)
XBIO : 3.85 (-2.78%)
Esperion Therapeutics: Q1 Earnings Snapshot

Esperion Therapeutics: Q1 Earnings Snapshot

ESPR : 2.37 (+11.79%)
Stevanato Group (STVN) Q1 Earnings Lag Estimates

Stevanato (STVN) delivered earnings and revenue surprises of -7.69% and 1.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

STVN : 27.64 (+3.64%)
ESPR : 2.37 (+11.79%)
Esperion Therapeutics (ESPR) Down 74.3% Since Last Earnings Report: Can It Rebound?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ESPR : 2.37 (+11.79%)
Esperion (ESPR) Plummets 54% Over Milestone Payment Row

An SEC filing by Esperion (ESPR) reveals that partner Daiichi Sankyo disagrees with the company's assessment that cardiovascular outcome CLEAR study data would support milestone payments.

ADPT : 3.11 (-3.42%)
ESPR : 2.37 (+11.79%)
ATRA : 0.6000 (-4.73%)
RCEL : 9.37 (+5.28%)

Barchart Exclusives

Should Amazon Stock Follow The ‘Magnificent 7’ Trend and Start Paying a Dividend?
While fellow 'Magnificent 7' peers like Alphabet and Meta Platforms have recently initiated dividends, Amazon might not do so for at least the next couple of years. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar